03.25.19
Swedish Biomimetics 3000 Ltd. (SB 3000) has developed μLOT, a new approach to manufacturing therapeutic peptides, which promises to replace traditional large scale batch manufacturing. The µLOT technology platform provides continuous manufacturing of peptides, enabling in-line process analytical technologies (PAT) throughout the process providing quality and control, as well as reduction in cost of goods, according to the company.
Peptide based medicines are widely used across many therapeutic areas including cancer, diabetes and autoimmune diseases due to their broader therapeutic window when compared to small molecule drugs. The market for peptide medications is projected to rise to $46 billion by 2025.
SB 3000 developed the technology, which is designed to significantly lower the cost, speed up the development of new therapeutic peptides, and introduce new important parameters in peptide manufacturing, with the goal of creating a paradigm shift improving quality control, cost of goods and environmental impact.
Jens Burkinsky, CTO of SB3000 Ltd. said, “We believe that the μLOT process can not only speed up development and reduce cost but also enable the synthesis of drugs that are currently not economically or technically possible to produce. At present we project the μLOT process being applied to 80% of the market but are further developing the technology to cover the remaining market by also including novel peptide designs such as lipid- and antibody-conjugations used in modern peptide drug delivery concepts.”
Click here to view infographic
Peptide based medicines are widely used across many therapeutic areas including cancer, diabetes and autoimmune diseases due to their broader therapeutic window when compared to small molecule drugs. The market for peptide medications is projected to rise to $46 billion by 2025.
SB 3000 developed the technology, which is designed to significantly lower the cost, speed up the development of new therapeutic peptides, and introduce new important parameters in peptide manufacturing, with the goal of creating a paradigm shift improving quality control, cost of goods and environmental impact.
Jens Burkinsky, CTO of SB3000 Ltd. said, “We believe that the μLOT process can not only speed up development and reduce cost but also enable the synthesis of drugs that are currently not economically or technically possible to produce. At present we project the μLOT process being applied to 80% of the market but are further developing the technology to cover the remaining market by also including novel peptide designs such as lipid- and antibody-conjugations used in modern peptide drug delivery concepts.”
Click here to view infographic
